NL-OMON42954已完成不适用
An open-label, single-dose, parallel-arm study to evaluate the pharmacokinetics and absolute bioavailability of GBR 830 following single dose administration by the subcutaneous (SC) route - GBR 830 pharmacokinetics, absolute bioavailability and safety study
Glenmark Pharmaceuticals SA0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy volunteers
- •18-55 years, inclusive
- •BMI: 18.5-32.0 kg/m2, inclusive
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 0.45 liters of blood in the 3 months prior the start of this study.
研究者
相似试验
进行中（未招募）
不适用
Study to investigate the effect of liver impairment on the way the body eliminates the drug BAF312 in patients with mild, moderate and severe liver impairment compared to healthy persons.subjects with mild (Group 1), moderate (Group 2), and severe (Group 3) hepatic impairment.EUCTR2012-000562-37-HUovartis Pharma Services AG48
进行中（未招募）
不适用
A study to assess the pharmacokinetics of LCZ696 in subjects with hepatic impairment compared to matched healthy subjectsMild and moderate hepatic impairmentMedDRA version: 14.1Level: PTClassification code 10024670Term: Liver disorderSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2012-000983-27-DEovartis Pharma Services AG32
招募中
1 期
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964)Healthy Adult ParticipantsCTIS2022-502952-30-00Janssen - Cilag International32
已完成
不适用
An open-label, parallel-group, single-dose study to evaluate the absolute bioavailability and tolerability of subcutaneous UCB4940 in healthy subjectsrheumatoid arthritisNL-OMON41792CB Celltech30
进行中（未招募）
1 期
An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic function and in subjects with normal hepatic functioActivated Phosphoinositide 3-Kinase Delta SyndromeMedDRA version: 20.0Level: PTClassification code: 10078281Term: Activated PI3 kinase delta syndrome Class: 100000004850CTIS2023-508519-22-00Pharming Technologies B.V.32